Switzerland approves Intercell's Japanese encephalitis vaccine
Vienna – Swissmedic has approved IXIARO®, a vaccine against Japanese encephalitis from Intercell AG that is distributed and marketed by Novartis AG. The decision by the Swiss authorities is another important milestone for the licensure process that has been initiated for selected attractive market segments. Intercell’s vaccine has already been approved and launched in the USA, Europe, Canada and Australia. IXIARO® is an inactivated vaccine for the active immunisation of adults against infections caused by the Japanese encephalitis virus.